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Abstract
Background: While multiple studies have examined the cost of health care for one
aspect of sickle cell disease care, few have focussed on the overall cost of comprehen-
sive care for sickle cell disease.
Methods:We conducted a retrospective cohort study of children with sickle cell dis-
ease treated in a comprehensive care centre from 1 January 2015 to 31 December
2016. Health care utilisation of included patients was based upon data from two main
sources. The clinical practice guideline was used to determine the expected resource
use of routine comprehensive care (planned elective care), and the financial claims
databasewas used to estimate real-world resource use associatedwith acute and inpa-
tient care (additional care).
Results: A total of 125 children with sickle cell disease were analysed. Expenditures
for these patients averaged €5049 [standard deviation (SD) €1634] per child per year.
Total yearly costs per patient varied considerably, ranging from €669 to €84 010, and
less than 15%of patientswere responsible for 50%of the health care costs. Themajor-
ity (37%) of costs was associated with inpatient hospital care, which increased by age
group, 27%with diagnostics, 19%with treatment, 11%with outpatients’ visits and 6%
with emergency care.
Conclusion:Wehave described real-world resource use and expenditures for children
with sickle cell disease in a European comprehensive care centre. It seems that costs
of a comprehensive approach with effective management in the outpatient setting is
favourable when compared to episodic health care.
KEYWORDS
comprehensive care, health care costs, resource use, sickle cell disease
Abbreviations: CPG, Clinical Practice Guideline for Paediatric Sickle Cell Disease; CPI,
consumer price index; HSCT, haematopoietic stem cell transplantation;WHO,World Health
Organisation
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1 INTRODUCTION
1.1 Sickle cell disease
Sickle cell disease is an autosomal, recessively inherited
haemoglobinopathy characterised by chronic haemolytic anaemia,
painful vaso-occlusive crises and progressive organ failure leading
to decreased life expectancy. It is the most common monogenetic
disease worldwide with an estimated 350 000 births annually and
an important public health problem according to the World Health
Organisation (WHO).1
Ninety percent of the global burden of sickle cell disease occurs
in sub-Saharan Africa, where the majority of children with the
disease do not live beyond 5 years of age.1,2 In contrast, life
expectancy in well-resourced countries has significantly improved
with almost all infants surviving into adulthood.3 Nevertheless, in
these countries, life expectancy of patients with sickle cell dis-
ease is still 20 years shorter than the average life span of healthy
adults.4
In the Netherlands, approximately 1500 individuals currently have
sickle cell disease, of which half are children and the carrier incidence
is 0.4%.5,6 Most of those affected are from Surinam, Asian or African
ancestry, with a minority being of Afro-Caribbean or Middle-Eastern
descent.7 More than a quarter of Dutch patients are treated in one of
the largest comprehensive sickle cell centres in the Netherlands – the
Erasmus University Medical Center-Sophia Children’s Hospital (Eras-
musMC). To ensure consistency in comprehensive care and reduce lev-
els of morbidity and mortality,8 all children with sickle cell disease in
theNetherlands are treated according to the national ‘Clinical Practice
Guideline for Paediatric Sickle Cell Disease’ (CPG; Table 1).9
1.2 Cost of health care
Generally, sickle cell disease together with its related comorbidi-
ties and complications results in high utilisation of medical resources
such as emergency room visits and hospitalisation.10-12 Knowledge of
expenditures associated with sickle cell disease can be used to serve
TABLE 1 Summary of the clinical standard treatment guideline for paediatric sickle cell disease in the Netherlands
Frequency
Items Birth-12mths 12mths-5 yrs 5-13 yrs 13-19 yrs
Laboratory analyses
- Complete blood count 3× 4× 4× 6×
- Red blood cell indices 3× 4× 4× 6×
- Low-density lipoprotein 2× 4× 4× 6×
- Bilirubin 2× 4× 4× 6×
- Liver and renal panel 2× 4× 4× 6×
- Iron status NA 4× 4× 6×
- Folic acid and cobalamin NA 4× 4× 6×
Haemoglobinopathy specific analyses
- Haemoglobin phenotyping 2× 1× NA NA
- Haemoglobin genotyping 1× NA NA NA
- Alpha thalassemia genetic mutations panel 1× NA NA NA
- Glucose-6-phosphate dehydrogenase enzyme deficiency testing 1× NA NA NA
Clinical geneticist outpatient visit 1× NA NA 1×
Paediatric haematologist outpatient visit 4× 8× 16× 12×




Transcranial Doppler NA 4× 13× 6×
Chest X-ray NA NA NA 1×
Electrocardiography NA NA NA 1×
Abdominal ultrasound NA NA NA 1×
Echocardiography NA NA 2× 1×
Ophthalmic screening NA NA NA 4×
Abbreviations: mths, months; NA, not applicable; yrs, years.
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as an incentive for further improvement of prevention and manage-
ment strategies for disease symptoms and complications, resulting in
both better care and reduced costs. In addition, estimating cost of
care is important as it may ensure appropriate allocation of resources
and reimbursement tariffs. However, most cost-of-care studies have
focussed on only one or two aspects of care, such as hospitalisations
and physician visits,13-17 and few studies have examined health care
expenditures exclusively for children. Moreover, the majority of stud-
ies are based on data from Northern America,12,18-21 and due to large
differences in health care systems, economic evidence of costs might
not be generalizable to European countries.
1.3 Study aims
Primary aims of this study were to (a) investigate overall cost of health
care resource use for paediatric patients with sickle cell disease in a
European country, and to (b) identify major cost drivers.
2 METHODS
We retrospectively estimated health care costs of a paediatric cohort
with sickle cell disease at the Erasmus MC by quantifying and valuing
resource use for a period of 24months.
2.1 Study population
All children with sickle cell disease visiting the Erasmus MC for rou-
tine or emergency care in 2017 were included in the study cohort.
Individual patient-level data were retrospectively analysed from the
period 1 January 2015 to 31 December 2016 [ie, 24 months]. Patients
were categorised into four age groups: (A) <1 year, (B) ≥1-5 years, (C)
≥5-13 years and (D) ≥13-19 years to reflect the categorisation of age
used in the CPG. Unless patients were born during the observation
period, they all contributed 24 months of follow-up time. To account
for a shorter follow-up time of newborn patients and a possible switch
between age groups during followup,we calculated theweighted aver-
age of all costs.Weightswere based on the patient-months-at-risk dur-
ing the retrospective study period (ie 24months).
2.2 Resource use
Resource use per patientwas quantified for fivemain resource use cat-
egories based on twomain data sources.
The two main sources of data included the national CPG, and the
Erasmus MC financial claims database. The five resource use cate-
gories included diagnostics, emergency roomvisits, inpatient care, out-
patient care and treatment.
The CPGwas used to determine the expected resource use of routine
comprehensive care (planned elective care) for the categories of diag-
nostics, outpatient visits and inpatient visits. This implied that every
childwith sickle cell disease follows recommendations for healthmain-
tenance and monitoring of disease-modifying therapy, and therefore
alsouses all resources andgenerates all costs. Consequently, a full com-
pliance to CPG was assumed. In addition to the resource use stated in
the CPG, the ErasmusMC employs a specialised paediatric nurse prac-
titioner (0.8 full-timeequivalent) for both inpatient andoutpatient care
coordination of childrenwith sickle cell disease.We assumed 45min of
working time for the nurse practitioner per planned outpatient visit for
elective care (ie, CPG). Remaining costs were distributed over all non-
elective outpatient (90%) and inpatient visits (10%) as obtained from
the financial claims database.
The Erasmus MC financial claims database was used to estimate
real-world resource use associatedwith acute and inpatient care for all
five resource use categories. This database contained all recorded hos-
pital procedures and visits to the ErasmusMC and all inpatient visits at
local hospitals. For the latter, we had no access to detailed information
about the inpatient episodes. Recorded resource use from the Eras-
musMCfinancial claimsdatabase that exceeded theexpected resource
use in frequency was regarded as resource use additional to CPG. For
instance, children below 1 year of age were expected to have five (rou-
tine) outpatient visits per year. In case a child in this age grouphadeight
recorded outpatient visits in 1 year, only three were regarded as addi-
tional visits to the CPG.
The included items for CPG and financial claims database per
resource use category are summarised in Table 2.
2.3 Resource valuation
Prices for the resource use category ‘diagnostics’ were based on tariffs
published by the Dutch Healthcare Authority (NZa) in 2019.22 Since
prices for haemoglobin phenotyping and haemoglobin genotyping
were not available from this source, they were based on local, internal
prices. Medication prices were acquired from the Dutch Healthcare
Insurance Board.23 Prices for surgical procedures (eg, cholecystec-
tomy)were based on prices published in 2017 byNZa.24 Costs for both
outpatient and inpatient visits were calculated in accordance with the
Dutch costing manual.25 The salary for a specialised paediatric nurse
practitioner was taken from the Dutch collective labour agreement for
hospitals (CAO).26
Prices for the resource categories of emergency room visits, outpa-
tient care and inpatient care are summarised in Table 3.
Where relevant, prices were indexed to 2019 euros using the per-
tinent consumer price index (CPI) published by Statistics Nether-
lands (CBS).27 All statistical analyses were performed in R (version
3.6.1) using R Studio (version 1.2.1335) (Supporting Information S1
for loaded R packages). All variables were analysed using descrip-
tive statistics. Categorical variables are presented in percentages
and (total) numbers. Continuous variables such as resource use fre-
quencies and costs are summarised by weighted means and standard
deviations (SD). Summary statistics are presented in an aggregated
way (ie, across all resource use categories) for the overall cohort.
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TABLE 2 Resource use categories and included items per data source
Resource use
category Items CPG Items financial claim database
Diagnostics Diagnostic procedures (including laboratory
and diagnostic imaging)
Additional diagnostic procedures (ie, X-rays, abdominal
ultrasound)
Treatment Standardmedication and vaccinations Additionally prescribedmedication, surgery and blood
transfusions
Emergency care NA Emergency room visits
Outpatient care Routine visits to the outpatient clinic and
care by specialised paediatric nurse
practitioner
Additional visits to the outpatient clinic or medical social work
and additional care by specialised paediatric nurse
practitioner
Inpatient care NA Inpatient visits (including ICU) and day patient visits
Abbreviations: CPG, clinical practice guideline; ICU, intensive care unit; NA, not applicable.













Emergency room visit NA 277 Dutch costingmanual25
Inpatient care Inpatient day at
academic hospital
NA 669 Dutch costingmanual25
ICU visit NA 2309 Dutch costingmanual25
Inpatient day at local
hospital
NA 473 Dutch costingmanual25





















25 Dutch collective labour
agreement for hospitals26
Abbreviations: CPG, clinical practice guideline; ICU, intensive care unit.
aAll care took place at the ErasmusMC - Sophia Children’s Hospital, except for inpatient days at a local hospital.
Weighted mean costs are presented per age group and resource use
category.
3 RESULTS
A total of 125 patients were retrospectively analysed based on the
Erasmus MC financial claim database. The mean age was 7.9 years
(SD: 4.7 years) on 31 December 2015 (first year of observation) and
8.6 years (SD: 4.9 years) on 31 December 2016. Forty-three percent
were female patients, and five patients entered the cohort as new-
borns in 2015 and 2016. Summary statistics for patient’s age, sex
and haemoglobin genotype at the end of the observation period (31
December 2016) are shown in Table 4 (see Supporting Information S2
for additional information on the distribution of genotypes across age
groups).
Overall, 52of125patients (43%)had inpatient careduring the study
period. These patients had a total of 133 admissions with an average
length of stay of 5.2 days (SD: 4.6). On average, children were seen
on an outpatient basis 2.1 times per year and admitted as inpatients
3.1 times per year. Patients in age groups A and B had no additional
outpatient visits to the planned visits according to the CPG. For age
groups C and D, the average yearly additional outpatient visits were
marginal. The number of patients per age group, their mean years at
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Haemoglobin genotype, n (%)
HbSS 76 (60.8)
HbSC 31 (24.8)
HbSβ+ thalassemia 8 (6.4)
HbSβ0 thalassemia 4 (3.2)
Other (ie, HbSdeltaβ0, HbArabβ0) 6 (4.8)
risk and summary statistics for inpatient and outpatient visits are pre-
sented in Table 5.
All patients (n = 125) accrued total cumulative costs of €1 205 919
during the 2 years observed. For patients with a full follow-up time (ie,
24 months), yearly total costs per patient varied considerably, rang-
ing from €669 to €84 010. Of the total expenditures for all patients,
approximately 50%of the costswere induced by18 children (ie, 14%of
the total patient population) and approximately 80% of the costs were
inducedby65 children (ie, 52%of all patients). ThedistributionofHbSS
and HbSC genotypes in the 18 children inducing 50% of the total costs
was 83.3 and 11.1%, respectively.
Average yearly expenditures for all 125 children were €5049 (SD:
€1634). The majority (37%) of costs was associated with inpatient
care: 27% with diagnostics, 19% with treatment, 11% with outpatient
care and 6% with emergency room visits. The average yearly costs per
patient and age group are depicted in Figure 1. Again, average costs
vary considerably between age groups, which is mainly related to dif-
ferences in the number of inpatient days. Major cost drivers for age
groups A and B were diagnostics and treatment, respectively. For age
groups C and D, the major cost drivers were inpatient care, although
for age group C, the average difference in costs between diagnostics
(€1355) and inpatient care (€1488) could be regarded as marginal.
Average yearly costs for inpatient care were higher in older age groups
and nearly three times as high in age group D compared to group C.
Only for age groups C and D, we observed stays at the intensive care
unit (resource use category inpatient care) with a slight increase from
age groups C and D. More information on the distribution of inpatient
care across age groups can be found in Supporting Information S3.
4 DISCUSSION
4.1 Health care utilisation and expenditures
Although health care utilisation and costs among children with sickle
cell disease have been studied previously,12,18-21 studies from Euro-
pean comprehensive care centres are scarce and have only focussed
on one aspect of care such as hospitalisations costs.14,28 To our
knowledge, this is the first study describing costs from a European
comprehensive care centre combining standard treatment costs with
real-world resource use.
The total yearly costs of health care for children with sickle cell dis-
ease, including inpatient care, outpatient care, diagnostics and treat-
ment averaged €5049 (SD: €1634) per patient per year. This is much
lower when compared to cost of health care for paediatric patients
with sickle cell disease in other studies. Kauf et al calculated total costs
of health care for children with sickle cell disease aged 0-9 years to be
US $10 704 (€8906) [SD: US $24 696 (€20 548)] per year, of which
more than 75% were associated with inpatient care.12 In our study,
inpatient care accounts for amuch smaller proportion of total costs (ie,
37%). As a consequence, this substantially reduces health care costs as
inpatient care is generallymore expensive compared to comprehensive
health care at specialised outpatient clinics. The study of Pizzo et al is
up until now the only cost of care study in sickle cell disease performed
in Europe. They retrospectively assessed the cost of inpatient care for
vaso-occlusive crises in the United Kingdom between 2010 and 2011.
For children aged 1-9 years, they reported mean admission costs to be
GB £1732 (€2379, 2019). Their analysis underestimates the real costs
























person per year (n)
Total
a
125 1.9 496 2.1 749 3.1 253 1.1
A 17 0.5 47 5.0 10 1.1 32 3.4
B 49 1.4 168 2.5 122 1.8 90 1.3
C 69 1.7 194 1.7 302 2.6 67 0.6
D 29 1.6 87 1.8 315 6.6 64 1.3
aThe sum of patients in each age group is not equal to the total number of patients studied, since children were analysed in older age groups when applicable
during the 24-month observation period. The mean number of visits was calculated by dividing the total number of visits (per stratum) by the total years at
risk (not the total number of patients), as some patients did not contribute an entire 2 years to each age group (due to increasing age and switching between
categories).
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F IGURE 1 The average yearly costs per patient and age group. Green: Yearly mean costs according to the clinical practice guideline. Red:
Yearly additional mean costs based on the ErasmusMedical Center financial claims database
of inpatient care, as it only considers the cases with crises as a primary
diagnosis.14 In our study, average yearly inpatient costs for children
aged 1-5 (age group B) and 5-13 (age group C) years old was €1061
and €1488, respectively. However, care should be given to comparing
costs, as factors such as health care financing, social and political struc-
tures as well as types of treatment regimen can vary greatly among
different countries. For example, due to differences in expert opinion,
the most recent guideline of the National Heart, Lung and Blood Insti-
tute advices transcranial Doppler screening every year, compared to
twice a year in the Dutch CPG. Furthermore, most cost-of-care stud-
ies use the terms cost, charge and fees synonymously or confuse reim-
bursement with costs, making it even harder to compare international
data.29
Sickle cell disease varies greatly in severity, with some children rel-
atively asymptomatic while others are severely ill. As a consequence,
substantial variation in health care costs is observed among children
with sickle cell disease.13,18,19,21 We also observed this variation; a rel-
atively small fractionof patients accounted for half of the total costs (ie,
18 children generating approximately 50% of the costs). Although our
study did not collect data on clinical heterogeneity (eg, organ damage),
these 18 patients are most likely patients with more severe symptoms.
Furthermore, themajority of these 18 patients hadHbSS sickle cell dis-
ease,which is oftenassociatedwith amore severephenotype. Toestab-
lish and quantify the effect of disease severity on health care costs, fur-
ther studieswith larger sample sizes and longer follow-up periods need
to be conducted.
Although the clinical features of sickle cell disease are heteroge-
neous, and therefore also the associated costs both within and across
age groups, yearly additional mean costs based on the financial claims
database seemed to increase with age for all resource use categories.
This is consistent with previous research showing that age is an impor-
tant determinant of disease severity, since older patients are more
likely to accumulate organ damage and dysfunction and have more
frequent painful vaso-occlusive crises.30-34 However, yearly additional
mean costs for emergency room visits follow a reverse trend (ie,
decrease between age groupsA toC),while they increase for age group
D again. A similar pattern is seen in the general paediatric population,
inwhich young children also constitute a disproportionately high share
of paediatric emergency care,mostly due to respiratory infections.35,36
In addition, parents tend to be more anxious when their child has just
been diagnosedwith sickle cell disease (via the newborn screening pro-
gram), possibly leading tomore frequent hospital visits.
THIELEN ET AL. 7 of 8
Estimating cost of care is important for appropriate allocation
of resources and reimbursement tariffs. Furthermore, specific to
the health care system in the Netherlands, knowledge of health
care utilisation and expenditures for patients with sickle cell dis-
ease may help to establish a diagnosis treatment combination (DBC)
for (paediatric) patients with sickle cell disease. DBCs describe a
complete care episode and are used as the basis for remuneration
negotiations between hospitals and health care insurers. Currently,
haemoglobinopathies (including sickle cell disease and thalassemia) do
not have a separate DBC code and are declared by the DBC ‘anaemia
not otherwise specified’. We hope this study will play a role in the
authorisation of a DBC for paediatric sickle cell disease, by giving
insight into overall cost of health care resource use for sickle cell dis-
ease patient in the Netherlands.
4.2 Limitations
This study is notwithout limitationswhich need to be consideredwhen
interpreting the results. Firstly, it is important to note that our analyses
do not aim at deriving statistical inference and therefore our results
are descriptive in nature. Secondly, sample size (125 patients), infor-
mation about patient characteristics, and follow-up time (24 months)
were limited. A further stratification into subgroups according to
potential cost predictors was therefore not possible. Thirdly, a sub-
stantial proportion of patients were admitted to local hospitals. There
are more than 10 local shared care centres, all with their own medical
databases, which are not linked to the financial claims database of
the Erasmus MC. Although inpatient days were manually retrieved,
detailed information about those care episodes, especially with regard
to treatment and diagnostics, is missing. Hence, the estimated total
costs reported for these items should be seen as lower limits of the
actual costs. For example, althoughmost complex care have been given
at the Erasmus MC, some children may have had a blood transfusion
or imaging procedures during admissions at a local hospital. These
interventions remain unknown and are therefore not reflected in the
total costs. Nevertheless, by including the major cost driver (inpatient
days in local hospital), we believe that results will not be substantially
different. The Sickle Cell Outcome REsearch (SCORE) consortium of
the Netherlands is currently developing a multicentre database for
(paediatric) sickle cell patients,which is an important step towardmore
detailed analysis of patient-related data. Fourthly, none of the patients
in our cohort had a haematopoietic stem cell transplantation (HSCT)
during the observed time period. Although HSCT is still a relatively
uncommon treatment, median total costs for children with sickle cell
disease is around US $413 000 (€343 627) for inpatient care and US
$18 000 (€14 977) for outpatient care,37 which would consequently
have increased total annual costs when performed. Finally, it is impor-
tant to note that we have adopted a health care perspective approach,
meaning that patient’s costs (ie, patient’s time lost from school, trans-
portation costs and parental loss of wage earning capacity due to
caretaking of a chronically sick child) were not accounted for in calcu-
lations. Further research iswarranted to determine this important cost
component.
5 CONCLUSION
In summary, we have described a detailed investigation of resource use
and cost of health care for paediatric patients with sickle cell disease
in the Netherlands over a 2-year period, retrospectively. Sickle cell
disease is a chronic, complex and often unpredictable disease requiring
life-long management. Our analyses suggest that costs of a compre-
hensive, multidisciplinary approach with effective management in the
outpatient setting is favourable when compared to episodic health
care. Lower resource use and costs were observed for acute care
and inpatient facilities. However, care should be given with regard
to comparing our data to other countries. Further studies including
more patients with longer follow-up times are needed to confirm our
findings. In addition, to enhancemedical outcomes anddecrease health
care utilisation and costs, further investigation of the small subset of
childrenwho consume a large percentage of the resources is required.
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